Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Oral E1018 in Healthy Adult Subjects
NCT06854042Phase 1Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of e 1018 in malaria (4 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Dose-limiting Events, Number of Participants With Adverse Events (Serious and Non-serious) and 12 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
e 1018
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06854042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854042.